Cargando…
Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends
Physiologically-based pharmacokinetics (PBPK) modeling is a robust tool that supports drug development and the pharmaceutical industry and regulatory authorities. Implementation of predictive systems in the clinics is more than ever a reality, resulting in a surge of interest for PBPK models by clin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582169/ https://www.ncbi.nlm.nih.gov/pubmed/34776945 http://dx.doi.org/10.3389/fphar.2021.708299 |
_version_ | 1784596927882461184 |
---|---|
author | Abouir, Kenza Samer, Caroline F Gloor, Yvonne Desmeules, Jules A Daali, Youssef |
author_facet | Abouir, Kenza Samer, Caroline F Gloor, Yvonne Desmeules, Jules A Daali, Youssef |
author_sort | Abouir, Kenza |
collection | PubMed |
description | Physiologically-based pharmacokinetics (PBPK) modeling is a robust tool that supports drug development and the pharmaceutical industry and regulatory authorities. Implementation of predictive systems in the clinics is more than ever a reality, resulting in a surge of interest for PBPK models by clinicians. We aimed to establish a repository of available PBPK models developed to date to predict drug-drug interactions (DDIs) in the different therapeutic areas by integrating intrinsic and extrinsic factors such as genetic polymorphisms of the cytochromes or environmental clues. This work includes peer-reviewed publications and models developed in the literature from October 2017 to January 2021. Information about the software, type of model, size, and population model was extracted for each article. In general, modeling was mainly done for DDI prediction via Simcyp(®) software and Full PBPK. Overall, the necessary physiological and physio-pathological parameters, such as weight, BMI, liver or kidney function, relative to the drug absorption, distribution, metabolism, and elimination and to the population studied for model construction was publicly available. Of the 46 articles, 32 sensibly predicted DDI potentials, but only 23% integrated the genetic aspect to the developed models. Marked differences in concentration time profiles and maximum plasma concentration could be explained by the significant precision of the input parameters such as Tissue: plasma partition coefficients, protein abundance, or Ki values. In conclusion, the models show a good correlation between the predicted and observed plasma concentration values. These correlations are all the more pronounced as the model is rich in data representative of the population and the molecule in question. PBPK for DDI prediction is a promising approach in clinical, and harmonization of clearance prediction may be helped by a consensus on selecting the best data to use for PBPK model development. |
format | Online Article Text |
id | pubmed-8582169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85821692021-11-12 Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends Abouir, Kenza Samer, Caroline F Gloor, Yvonne Desmeules, Jules A Daali, Youssef Front Pharmacol Pharmacology Physiologically-based pharmacokinetics (PBPK) modeling is a robust tool that supports drug development and the pharmaceutical industry and regulatory authorities. Implementation of predictive systems in the clinics is more than ever a reality, resulting in a surge of interest for PBPK models by clinicians. We aimed to establish a repository of available PBPK models developed to date to predict drug-drug interactions (DDIs) in the different therapeutic areas by integrating intrinsic and extrinsic factors such as genetic polymorphisms of the cytochromes or environmental clues. This work includes peer-reviewed publications and models developed in the literature from October 2017 to January 2021. Information about the software, type of model, size, and population model was extracted for each article. In general, modeling was mainly done for DDI prediction via Simcyp(®) software and Full PBPK. Overall, the necessary physiological and physio-pathological parameters, such as weight, BMI, liver or kidney function, relative to the drug absorption, distribution, metabolism, and elimination and to the population studied for model construction was publicly available. Of the 46 articles, 32 sensibly predicted DDI potentials, but only 23% integrated the genetic aspect to the developed models. Marked differences in concentration time profiles and maximum plasma concentration could be explained by the significant precision of the input parameters such as Tissue: plasma partition coefficients, protein abundance, or Ki values. In conclusion, the models show a good correlation between the predicted and observed plasma concentration values. These correlations are all the more pronounced as the model is rich in data representative of the population and the molecule in question. PBPK for DDI prediction is a promising approach in clinical, and harmonization of clearance prediction may be helped by a consensus on selecting the best data to use for PBPK model development. Frontiers Media S.A. 2021-10-28 /pmc/articles/PMC8582169/ /pubmed/34776945 http://dx.doi.org/10.3389/fphar.2021.708299 Text en Copyright © 2021 Abouir, Samer, Gloor, Desmeules and Daali. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Abouir, Kenza Samer, Caroline F Gloor, Yvonne Desmeules, Jules A Daali, Youssef Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends |
title | Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends |
title_full | Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends |
title_fullStr | Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends |
title_full_unstemmed | Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends |
title_short | Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends |
title_sort | reviewing data integrated for pbpk model development to predict metabolic drug-drug interactions: shifting perspectives and emerging trends |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582169/ https://www.ncbi.nlm.nih.gov/pubmed/34776945 http://dx.doi.org/10.3389/fphar.2021.708299 |
work_keys_str_mv | AT abouirkenza reviewingdataintegratedforpbpkmodeldevelopmenttopredictmetabolicdrugdruginteractionsshiftingperspectivesandemergingtrends AT samercarolinef reviewingdataintegratedforpbpkmodeldevelopmenttopredictmetabolicdrugdruginteractionsshiftingperspectivesandemergingtrends AT glooryvonne reviewingdataintegratedforpbpkmodeldevelopmenttopredictmetabolicdrugdruginteractionsshiftingperspectivesandemergingtrends AT desmeulesjulesa reviewingdataintegratedforpbpkmodeldevelopmenttopredictmetabolicdrugdruginteractionsshiftingperspectivesandemergingtrends AT daaliyoussef reviewingdataintegratedforpbpkmodeldevelopmenttopredictmetabolicdrugdruginteractionsshiftingperspectivesandemergingtrends |